June 2, 2026

FOR IMMEDIATE RELEASE

 

Silicogenix Announces Completion of First Function-Focused Kinome Library Covering More Than 450 Human Kinases

 

Milestone Advances Company's Vision of Programmable Drug Development and Hyper-Personalized Medicine

​

Burlingame, CA, June 2, 2026 — Silicogenix (SGX), a chemical biology company pioneering programmable drug development, today announced the completion of its first function-focused small molecule library targeting the majority of the human kinome, marking a significant milestone toward the company's long-term vision of enabling truly personalized medicine and ultimately approaching N-of-1 therapeutic design across human disease.

 

The newly completed SGX Kinome Library contains more than 5 million ligands against 466 experimentally accessible human kinases. Of the approximately 518 kinases encoded by the human genome (1), almost all selected targets within the library have commercially available assays, enabling rapid experimental validation through binding and functional studies.

 

"This achievement represents a foundational milestone for Silicogenix," said Shailesh Date, CEO & Co-Founder of Silicogenix. "Kinases play central roles in numerous diseases, yet large portions of the kinome remain under-explored from a therapeutic perspective. Our goal is to systematically expand the available chemical toolkit for biological discovery while creating the foundation for programmable, patient-tailored therapeutics."

 

Protein kinases are among the most important target classes in modern drug discovery. According to analyses by Lars Jensen and colleagues, approximately 85% of human kinases have been implicated in diseases or disorders that may be therapeutically addressed using selective inhibitors (2). Despite this, research efforts have historically concentrated on a relatively small subset of kinases, and recent studies estimate that only ~24% of the human kinome is currently covered by any chemical probes (3). The SGX Kinome Library seeks to address this gap by substantially increasing the number of experimentally testable kinase-targeting molecules available for research and therapeutic development, pending biological validation.

 

The library will become a core component of Silicogenix's proprietary Target-Ligand Pair (TLP) repository. TLPs serve as modular "chemical building blocks" that can be combined and recombined to interrogate biological systems using the company's many-to-many (M2M) discovery framework. By enabling simultaneous evaluation of multiple targets and pathways, the platform is designed to support the development of increasingly precise and individualized therapeutic strategies.

 

"The kinome library is just the tip of the iceberg," said Daniel Serna, Senior Engineer and lead researcher on the project. "This is the first in a series of specialized chemical matter libraries we plan to generate. Our objective is to systematically build the molecular infrastructure needed to make programmable medicine a reality."

 

Silicogenix is already expanding its efforts beyond kinases, with future libraries planned for additional therapeutically relevant target classes including G protein-coupled receptors (GPCRs), ion channels, and transporters.

 

According to Jose Jaramillo, CTO and Co-Founder, “these growing libraries of validated Target-Ligand Pairs will form a critical foundation for next-generation drug discovery.” He added, “This approach moves beyond the traditional one-target, one-drug paradigm and towards the next-generation of adaptive, systems-level therapeutic design.”

 

 

About Silicogenix

Silicogenix is a chemical biology company developing a next-generation, programmable drug discovery platform that integrates AI-driven molecular design, structured biological knowledge, and experimental validation. The company's mission is to create modular therapeutic building blocks that can be systematically combined to understand disease biology and enable the rational design of personalized medicines.

 

For more information, visit the company's website or follow Silicogenix on LinkedIn.

 

Media Contact

Silicogenix Inc.

Email: media-team (at) silicogenix (dot) com

​​

​

References

1.    Manning G. et al. The Protein Kinase Complement of the Human Genome. Science. 2002.

2.    Pletscher-Frankild S. et al. DISEASES: Text Mining and Data Integration of Disease-Gene Associations. Methods. 2015.

3.    Anderson N.A. et al. Coverage of the Human Kinome by Chemical Probes. Biochemical Journal. 2023.